


Executive Summary

Cancer is a set of extremely lethal diseases, connected with genetic “damage” of cells. Cancer is a second cause of mortality worldwide, taking almost 10 million lives annually. Today there is no single diagnostic or treatment method for all types of this disease. It has been proven beyond doubt that the earlier the disease is identified, the higher are the chances to be cured. Early cancer diagnostics is one of the greatest hopes of humanity in curing the disease; however, it remains problematic as clinical symptoms do not reveal themselves neither to patient, nor to doctor until it's too late. For decades scientists attempted to develop the accurate methods of early cancer diagnostics: great advancements have been made in disease understanding, but the problem remains unsolved. The hottest current approach to early cancers diagnostics is the method called “liquid biopsy” that consists in blood test looking for the traces of the cancer cells. Such approach has already been approved by FDA, but remains challenging because of numerous technological bottlenecks.

After 10 years of scientific research ARNA Genomics founders developed proprietary technological platform of liquid biopsy based on several breakthroughs, ranging from unique proprietary method of DNA amplification from the whole blood to defining the set of cancer DNAs, detection of which leads to confident diagnosis. The platform is truly fundamental and allows developing tests for many type of cancer, starting with the most notorious killers: cancers of lung, liver, pancreas, colon, ovary, and prostate. ARNA Genomics plans to produce these tests in timely manner, however, the current focus belongs to ARNA BC, the test for Breast Cancer, the nightmare of modern women. ARNA BC demonstrates superior sensitivity and validity in the laboratory testing and appears to functionally exceed all known tests for Breast Cancer.

Immediately upon token distribution completion, ARNA Genomics is ready to initiate regulatory registration followed by commercialization of ARNA BC. Our plan is to start in the United States, apply for FDA's Investigational Device exemption to prove the test superiority, safety, sensitivity and specificity through clinical trials under FDA 510(k) process. Upon clearing regulatory market pathway for ARNA BC, we would proceed with extending the method to additional cancers types, while at the same time establishing operations in China, India, and Europe.

While ARNA Genomics is fully equipped to go through the “official” medical device registration pathway, ARNA team came to recognize one of the most painful issues of the modern healthcare, that is an unfortunate population-wide lack of trust towards evidence-based diagnostics and treatments. The most striking example is the rising of self-treatment and alternative medicine movement. Thousands of new cancer patients intentionally disregard medical advice and keep practicing clinically unproven methods. Such people firmly believe that official clinical trials and




regulations are faulty and rigged by selection bias. They accuse pharmaceutical companies and regulators of hiding certain facts from the public, while displaying the facts that are beneficial to their business only. Massive resources are spent today to prevent such manipulations: CROs and governmental agencies audit and control each and every step of the healthcare product lifecycle. Still, the bitter problem remains and more and more people lose trust in the official system.

Even after ARNA BC test is officially validated and registered as medical diagnostics, there will be people who would not appreciate its potential and disbelieve the official clinical data. ARNA team respects such skeptical people as our peers, friends, and compatriots. We will not dismiss or abandon them. Therefore, in addition to classic evidence-based medicine market pathway ARNA aims to provide people with the instruments they can use to personally validate life-saving healthcare technologies such as ARNA BC. Here comes "the" Blockchain! To serve and benefit skeptical people who would like to make personal decisions on their healthcare treatment options, ARNA group decided to create a transparent manipulation-proof, temper/bias-free system that will give all patients the opportunity to personally validate the healthcare technology. We call it ARNA Panacea. We already build it on blockchain technology that is distinguished by combination of efficiencies in trust, transparency, privacy, and data management.

It may appear surprising that such diverse technologies as ARNA BC and ARNA Panacea come together in a single project, but those who followed our logics understand the elegance of the synergy of these two innovations. ARNA BC will be supported by ARNA Panacea to reach those users who would like to rely on their own judgment, while ARNA Panacea will be supported by ARNA BC to showcase the utility and excitement of the new approach to define clinical value. This duo is destined to unite the whole society at the new level of trust in healthcare technologies showcased by saving lives with the help of the new platform of cancer diagnostics.

The first working release of ARNA Panacea is planned for the middle of 2018. Approximately at the same time ARNA Genomics will be able to start the first commercial ARNA BC tests. If everything goes as planned, by the year of 2020 the world will witness rising of two new powerful tools of modern healthcare: the ARNA BC and ARNA Platform for cancer diagnostics and ARNA Panacea system for validating and unifying modern healthcare. Let us explain how exactly this will be accomplished:

- the first ARNA BC user's test results will be loaded into ARNA Panacea blockchain and stay there for some extended period of time
- in several months after the initial tests the ARNA BC results will be independently validated clinically to reveal the validity and sensitivity of the test. This follow-up data will be carefully recorded in the same ARNA Panacea blockchain



- in one year ARNA BC users will have sufficient data accumulated in ARNA Panacea to pull up Blockchain-recorded values and define the validity and sensitivity of the test themselves

We envision ARNA Panacea platform to eventually spread far beyond validating healthcare technologies and storing patient data. The system is expected to unite and serve the entire marketplace of global healthcare by providing multiple benefits to all stakeholders:

- patients will be excited by the ability to observe and validate the constantly growing set of facts on the efficacy of diverse treatments
- doctors will start using ARNA Panacea first as the storage of patient data and later as the tool to validate their own therapeutic successes
- insurance companies will follow patients and doctors to employ ARNA Panacea in patient management
- pharmaceutical companies will come to receive encrypted information about the modern state of the diseases and to recruit freshly diagnosed patients for all kind of research without revealing patient identity
- regulators will come to use ARNA Panacea data to establish safety and efficacy of healthcare technologies
- investors and scientists will join the community to exchange inventions and financing